Clinical trials: Dengue Fever
Dengue, Dengue Hemorrhagic Fever
Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
The study was designed to evaluate whether the first CYD dengue vaccination can be administered concomitantly with Stamaril® yellow fever vaccine during the same day and visit, but at 2 different sites of administration.
- Conditions
- Dengue, Dengue Hemorrhagic Fever, Yellow Fever
- Trial name
- NCT01436396
- Testing
- Live, attenuated dengue serotype 1, 2, 3, and 4 virus, Yellow fever vaccine, Measles, mumps, and rubella (MMR) vaccine
- Where
- 2 sites in Colombia, Peru
- Volunteers
- 792 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue, Dengue Fever
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia
The aim of the trial was to assess the efficacy of the CYD dengue vaccine in preventing symptomatic, virologically-confirmed dengue (VCD) cases.
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01373281
- Testing
- Live, attenuated, dengue serotype 1, 2, 3, 4 virus
- Where
- 12 sites in Indonesia, Malaysia and 3 more
- Volunteers
- 10,275 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy Volunteers
Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
The purpose of this study is to assess the cellular immune responses following 2 doses given 3 months apart of tetravalent dengue vaccine candidate (TDV) in 4 to 16 years' healthy participants.
- Trial name
- NCT02948829
- Testing
- TDV
- Where
- 2 sites in Panama, Philippines
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Takeda
Vector Borne Diseases
Characterization of Skin Immunity to Aedes Aegypti Saliva in Dengue-endemic Participants in Cambodia
Background: Mosquito-borne viruses like dengue cause major illness and death worldwide, particularly in Southeast Asia. When mosquitoes deliver a virus into the skin of humans, they also leave saliva.
- Trial name
- NCT04350905
- Testing
- Mosquito Feeding
- Where
- Cambodia
- Volunteers
- 42 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteers
Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector
The purpose of this study is to compare the safety, tolerability and immunogenicity of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) [previously DENVax] when administered intradermally in varied dosing schedules and via…
- Trial name
- NCT01765426
- Testing
- TDV
- Where
- 2 sites in United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever
Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever
The purpose of this study is to assess the safety of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) (previously DENVax) in healthy adults when given as either a subcutaneous (SC) or intradermal (ID) injection at two dose…
- Trial name
- NCT01224639
- Testing
- TDV - Low Dose, TDV - High Dose
- Where
- Colombia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Inviragen Inc.
Dengue Fever
Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults
The purpose of this study is to assess the neutralizing antibody response against each dengue serotype post-vaccination.
- Trial name
- NCT03746015
- Testing
- TDV
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia
The purpose of this study was to demonstrate that different CYD dengue vaccine lots manufactured using the same method and in the same location but at different times produce an equivalent immunological response after 3 doses.
- Trial name
- NCT01134263
- Testing
- Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus
- Where
- 8 sites in Australia
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®
The aim of the study was to assess the safety and immunogenicity of the CYD dengue vaccine and Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant) when administered concomitantly or…
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Human Papillomavirus Disease
- Trial name
- NCT02993757
- Testing
- CYD Dengue Vaccine, Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.
- Where
- 5 sites in Malaysia
- Volunteers
- 528 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever
Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years
The purpose of the study is to demonstrate the non-inferiority (NI) of the immune response to 2 doses of 9vHPV vaccine, 1 co-administered with TDV, compared with 2 doses of 9vHPV vaccine administered alone.
- Trial name
- NCT04313244
- Testing
- 9vHPV Vaccine, Dengue Tetravalent Vaccine (TDV)
- Where
- 4 sites in Thailand
- Volunteers
- 614 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue
An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge
The investigational study drug, JNJ-64281802, is being developed for the prevention and treatment of dengue infection. This study is hypothesizing that the highest dose of the investigational study drug is superior to receiving a…
- Trial name
- NCT05048875
- Testing
- Cohort 1 - Group 1 JNJ High Dose, Cohort 1 - Group 2 JNJ Medium Dose, Cohort 1 - Group 2 JNJ Low Dose
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age
The aim of the study was to assess the immune response and the safety of different vaccination schedules of CYD dengue vaccine. The primary objectives of the study were: To demonstrate the non-inferiority of the immune response…
- Trial name
- NCT02628444
- Testing
- CYD Dengue Vaccine
- Where
- 6 sites in Colombia, Philippines
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Chikungunya Virus, Dengue Virus
A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components
The rationale for a Treatment Use Investigational Device Exemption (IDE) of INTERCEPT PCs is to address current gaps in platelet transfusion safety in selected geographic regions.
- Trial name
- TRUE (NCT02305732)
- Testing
- INTERCEPT Platelets
- Where
- 8 sites in Puerto Rico
- Volunteers
- 90 people
- Sponsor
- Cerus Corporation
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®
The aim of this study was to investigate the immunogenicity and safety of CYD dengue vaccine and Cervarix when administered concomitantly or sequentially in healthy female participants aged 9-14 years of age.
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Human Papillomavirus Disease
- Trial name
- NCT02979535
- Testing
- CYD Dengue Vaccine, Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant
- Where
- Mexico
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever
Study of AT-752 in Patients With Dengue Infection
The Phase 2 study will be conducted in adult patients with confirmed Dengue infection and will investigate safety, PK, and pharmacodynamics (PD) in this population.
- Trial name
- NCT05466240
- Testing
- AT-752
- Where
- 32 sites in Brazil, Colombia and 8 more
- Volunteers
- 21 people
- Sponsor
- Atea Pharmaceuticals, Inc.
Dengue Fever
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults
The purpose of this study is to evaluate the safety and immune response of a naturally aged lot of tetravalent dengue vaccine (TDV) in healthy participants, aged 18 to 60 years, in non-endemic country(ies) for dengue.
- Trial name
- NCT03771963
- Testing
- Tetravalent Dengue Vaccine (TDV)
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Takeda
Viral Infection
Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
The objective is to evaluate the safety and tolerability of a single-ascending oral dose of UV-4B in healthy subjects and to determine pharmacokinetic parameters describing absorption and elimination following a single dose of…
- Trial name
- UV (NCT02061358)
- Testing
- UV-4B 3 mg, UV-4B 10 mg, UV-4B 30 mg
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Healthy Volunteers
A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India
The main aims of the study are to learn about side effects and a participant's immune response to Takeda's Dengue Vaccine when given twice within 3 months.
- Trial name
- NCT06060067
- Testing
- TDV
- Where
- 10 sites in India
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US
This study used 3 different formulations of tetravalent CYD dengue vaccine. The primary objective of the study was to evaluate the neutralizing antibody response after 2 doses of two different formulations of tetravalent dengue…
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus
- Trial name
- NCT00617344
- Testing
- Tetravalent CYD Dengue Vaccine , 5555 formulation, Tetravalent CYD Dengue Vaccine , 5553 formulation, Tetravalent CYD Dengue Vaccine, 4444 formulation
- Where
- 5 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dengue
A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults
This descriptive study will evaluate the safety and immunogenicity of 5 different formulations of the WRAIR dengue vaccine compared to a placebo.
- Trial name
- NCT00239577
- Testing
- Live attenuated tetravalent dengue vaccine
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline